Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma

Journal of the American Academy of Dermatology

Volumn 78, Issue 5, 2018, Pages 942-948

  Stiegel, Evan ^a   Xiong, David ^a   Ya, Jason ^a   Funchain, Pauline ^a   Isakov, Raymond ^a   Gastman, Brian ^a   Vij, Alok ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Breslow thickness; melanoma; melanoma prognosis; sentinel lymph node biopsy

Indexed keywords

ADULT; ARTICLE; BRESLOW THICKNESS; COHORT ANALYSIS; CUTANEOUS MELANOMA; CUTANEOUS PARAMETERS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROMETASTASIS; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; ULCER; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; LYMPH NODE; LYMPH NODE METASTASIS; MELANOMA; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR; SURVIVAL RATE; TUMOR INVASION;

ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 85047539246     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2018.01.030     Document Type: Article

References (28)

1. Morton, D.L., Wen, D.R., Wong, J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:4 (1992), 392–399.
2. Morton, D.L., Thompson, J.F., Cochran, A.J., et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:7 (2014), 599–609.
3. Soong, S.J., Shaw, H.M., Balch, C.M., et al. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 16:2 (1992), 191–195.
4. Barnhill, R.L., Fine, J.A., Roush, G.C., et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78:3 (1996), 427–432 Erratum in: Cancer. 1997;79(2):423.
5. Schuchter, L., Schultz, D.J., Synnestvedt, M., et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 125:5 (1996), 369–375.
6. Balch, C.M., Gershenwald, J.E., Soong, S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:36 (2009), 6199–6206.
7. Freeman, S.R., Gibbs, B.B., Brodland, D.G., et al. Prognostic value of sentinel lymph node biopsy compared with that of BT: implications for informed consent in patients with invasive melanoma. Dermatol Surg 39:12 (2013), 1800–1812.
8. National Comprehensive Cancer Network (NCCN). Melanoma, version 1.2018. Available from: https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed December 24, 2017.
9. Coit, D.G., Andtbacka, R., Anker, C.J., et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:4 (2013), 395–407.
10. Calista, D., Vitali, P., Low predictive value of sentinel lymph node biopsy in patients with thin melanoma. Int J Dermatol 56:1 (2017), e6–e7.
11. Cordeiro, E., Gervais, M.K., Shah, P.S., et al. Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis. Ann Surg Oncol 23:13 (2016), 4178–4188.
12. Wright, B.E., Scheri, R.P., Ye, X., et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 143:9 (2008), 892–899 discussion 899-900.
13. Han, D., Zager, J.S., Shyr, Y., et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 31:35 (2013), 4387–4393.
14. Wong, S.L., Brady, M.S., Busam, K.J., et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 13:3 (2006), 302–309.
15. Gershenwald, J.E., Colome, M.I., Lee, J.E., et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16:6 (1998), 2253–2260.
16. Thomas, J.M., Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 5:1 (2008), 18–23 Review.
17. Kachare, S.D., Singla, P., Vohra, N.A., et al. Sentinel lymph node biopsy is prognostic but not therapeutic for thick melanoma. Surgery 158:3 (2015), 662–668.
18. Gajdos, C., Griffith, K.A., Wong, S.L., et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?. Cancer 115:24 (2009), 5752–5760.
19. Carlson, G.W., Murray, D.R., Hestley, A., et al. Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it?. Ann Surg Oncol 10:4 (2003), 408–415.
20. Scoggins, C.R., Bowen, A.L., Martin, R.C. 2nd, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg 145:7 (2010), 622–627.
21. Kirkwood, J.M., Manola, J., Ibrahim, J., et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:5 (2004), 1670–1677.
22. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375:19 (2016), 1845–1855.
23. van der Ploeg, A.P., van Akkooi, A.C., Haydu, L.E., et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer 50:1 (2014), 111–120.
24. Grabowski, J., Saltzstein, S.L., Sadler, G.R., et al. A comparison of Merkel cell carcinoma and melanoma: results from the California Cancer Registry. Clin Med Oncol 2 (2008), 327–333.
25. Gerami, P., Cook, R.W., Wilkinson, J., et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 21:1 (2015), 175–183.
26. Gerami, P., Cook, R.W., Russell, M.C., et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72:5 (2015), 780–785.
27. Hsueh, E.C., DeBloom, J.R., Lee, J., et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol, 10(1), 2017, 152.
28. Ferris, L.K., Farberg, A.S., Middlebrook, B., et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. J Am Acad Dermatol 76:5 (2017), 818–825.